Oncology “First Launch” and Partnering

1:45 PM - 2:45 PM, Wednesday, June 5,2019 ・ 105AB, Level 100
With multiple oncology "first launch" successes in recent years, most oncology emerging pharma company boards and executive teams will consider this increasingly attractive path to commercialization, often in parallel to partnering. Data shared during this panel, from all US oncology emerging pharma "first launches," will support discussion topics including: US, EU and RoW first launch benchmarks, preparing to launch vs exit or co-promote, special challenges in personalized medicine, rare oncology indications and "novel" technologies and innovation in “first launches” (customer experience, multi-channel commercial models and the role of analytics, AI and machine learning).
Speakers
photo
VP, Commercial
Loxo Oncology
photo
Chief Commercial officer
G1 Therapeutics
photo
VP and Head of Commercial
Tocagen
photo
Senior Vice President, Head of Commercial for Immunoscience, Cardiovascular and Fibrosis
Bristol-Myers Squibb